PHILADELPHIA, Pa., Aug. 1, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, announced today that it has signed a license and supply agreement with Daewoong Pharmaceuticals Co. Ltd, a leading South Korean pharmaceutical company. Under terms of the agreement, Daewoong will commercialize, subject to regulatory approval, Eurand's novel extended-release (ER) formulation of the muscle relaxant Cyclobenzaprine HCl in South Korea. Cyclobenzaprine ER has been developed using Eurand's innovative Diffucaps(r) technology. Financial terms were not disclosed.
